Pure Global
NCT06081621

A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)

A Multi-center, Randomized, Double-Blinded, Parallel and Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy in Idiopathic Pulmonary Fibrosis (IPF) Patients
Regend Therapeutics·Phase 2·ClinicalTrials.gov·biologicalRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Idiopathic Pulmonary Fibrosis
Drug/Device/Intervention
REGEND001
Study type
Interventional
Intervention type
biological
Sponsor & location
Primary sponsor
Regend Therapeutics
Location
Beijing,Shanghai,Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
Oct 20, 2023
End date
Dec 01, 2024
Enrollment
20 participants
Primary outcome

The ratio of subjects with improvement of lung carbon oxide diffusion function (DLCO)

Summary

Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease with injury of
 lung tissues. REGEND001 is a cell therapy product, made from bronchial basal cells with
 ability to regenerate lung tissue, is promising to IPF treatment. This is a multi-center,
 randomized, double-blinded, parallel and placebo-controlled phase II clinical study to
 evaluate the efficacy and safety of REGEND001 in IPF patients.

ICD-10 classifications
Other interstitial pulmonary diseases with fibrosisCystic fibrosis with pulmonary manifestationsCystic fibrosisGraphite fibrosis (of lung)Pulmonary heart disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06081621
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06081621 through Pure Global AI's free database. This Phase 2 trial is sponsored by Regend Therapeutics and is currently Recruiting. The study focuses on Idiopathic Pulmonary Fibrosis. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.